Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users
NCT ID: NCT00902772
Last Updated: 2009-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
100 participants
INTERVENTIONAL
2009-05-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users
NCT00828659
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
NCT03657355
A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users
NCT03286218
A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
NCT03509285
Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users
NCT01987739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Placebo
Placebo
B
Lorazepam
Lorazepam
mg, oral dose
C
Lorazepam
Lorazepam
mg, oral dose
D
Lorazepam
Lorazepam
mg, oral dose
E
AZD7325
AZD7325
mg, oral dose
F
AZD7325
AZD7325
mg, oral dose
G
AZD7325
AZD7325
mg, oral dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lorazepam
mg, oral dose
AZD7325
mg, oral dose
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) within the range of 19.0 to 33.0 kg/m2, inclusive, and a minimum weight of 50.0 kg at screening
* Willing and able to abide by all study requirements and restrictions
Exclusion Criteria
* Positive breath alcohol test prior to dosing
* Clinically significant abnormalities on physical examination, medical history, 12-lead ECG, vital signs, or safety laboratories
18 Months
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Myroslava K Romach, MD
Role: PRINCIPAL_INVESTIGATOR
Kendle Early Stage - Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1140C00008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.